



Clinical trial results:

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of PRV-015 in Adult Patients with Non-Responsive Celiac Disease as an Adjunct to a Gluten-free Diet

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2020-000649-16 |
| Trial protocol | NL ES |
| Global end of trial date | 30 July 2024 |

Results information

| | |
|--------------------------------|--|
| Result version number | v2 (current) |
| This version publication date | 25 December 2025 |
| First version publication date | 13 August 2025 |
| Version creation reason | <ul style="list-style-type: none">• Correction of full data set No data was updated. Minor updates were made to descriptions in Population of Trial Subjects, Screening Details, and End Points. |

Trial information

Trial identification

| | |
|-----------------------|--------------|
| Sponsor protocol code | PRV-015-002B |
|-----------------------|--------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT04424927 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Provention Bio, Inc. |
| Sponsor organisation address | 55 Broad Street, 2nd Floor, Red Bank, New Jersey, United States, 07701 |
| Public contact | Trial Transparency Team, Sanofi aventis recherche & développement, Contact-US@sanofi.com |
| Scientific contact | Trial Transparency Team, Sanofi aventis recherche & développement, Contact-US@sanofi.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 07 November 2024 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 30 July 2024 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To assess the efficacy of PRV-015 in attenuating the symptoms of celiac disease in adult participants with nonresponsive celiac disease as measured by the Abdominal Symptoms domain of the celiac disease patient reported outcome (CeD PRO) questionnaire.

Protection of trial subjects:

Participants were fully informed of all pertinent aspects of the clinical trial as well as the possibility to discontinue at any time in language and terms appropriate for the participant and considering the local culture. During the course of the trial, participants were provided with individual participant cards indicating the nature of the trial the participant is participating, contact details and any information needed in the event of a medical emergency.

Collected personal data and human biological samples were processed in compliance with the Sanofi-Aventis Group Personal Data Protection Charter ensuring that the Group abides by the laws governing personal data protection in force in all countries in which it operates.

Background therapy: -

Evidence for comparator: -

| | |
|---|----------------|
| Actual start date of recruitment | 24 August 2020 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | Canada: 17 |
| Country: Number of subjects enrolled | Netherlands: 1 |
| Country: Number of subjects enrolled | Spain: 42 |
| Country: Number of subjects enrolled | United States: 327 |
| Worldwide total number of subjects | 387 |
| EEA total number of subjects | 43 |

Notes:

Subjects enrolled per age group

| | |
|--|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 | 0 |

| | |
|--|-----|
| wk | |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 367 |
| From 65 to 84 years | 20 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

The study was conducted at 39 centers in 4 countries. A total of 648 participants were screened between 24 August 2020 and 16 January 2024, of which 255 participants were screen failures and 5 participants discontinued before run-in period. Screen failures were mainly due to not meeting eligibility criteria.

Pre-assignment

Screening details:

388 participants entered the placebo run-in period. 1 participant never received treatment and was not started after signing the ICF. 9 participants discontinued during run-in or were not dosed. 27 participants were run-in failures. 126 participants were randomization failures. A total of 226 participants were enrolled and randomized in the study.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Carer |

Arms

| | |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes |
| Arm title | Placebo |

Arm description:

Participants received placebo matching with PRV-015 subcutaneous (SC) injection every 2 weeks (q2w) in double-blind treatment period for 24 weeks.

| | |
|--|---------------------------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection/infusion |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Placebo SC injection q2w for 24 weeks.

| | |
|------------------|----------------|
| Arm title | PRV-015 100 mg |
|------------------|----------------|

Arm description:

Participants received PRV-015 100 milligram (mg) SC injection q2w in double-blind treatment period for 24 weeks.

| | |
|--|---------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | PRV-015 |
| Investigational medicinal product code | |
| Other name | Ordesekimab, AMG 714 |
| Pharmaceutical forms | Solution for injection/infusion |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

PRV-015 100 mg SC injection q2w for 24 weeks.

| | |
|------------------|----------------|
| Arm title | PRV-015 300 mg |
|------------------|----------------|

Arm description:

Participants received PRV-015 300 mg SC injection q2w in double-blind treatment period for 24 weeks.

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|---|---------------------------------|
| Investigational medicinal product name | PRV-015 |
| Investigational medicinal product code | |
| Other name | Ordesekimab, AMG 714 |
| Pharmaceutical forms | Solution for injection/infusion |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: PRV-015 300 mg SC injection q2w for 24 weeks. | |
| Arm title | PRV-015 600 mg |

Arm description:

Participants received PRV-015 600 mg SC injection q2w in double-blind treatment period for 24 weeks.

| | |
|--|---------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | PRV-015 |
| Investigational medicinal product code | |
| Other name | Ordesekimab, AMG 714 |
| Pharmaceutical forms | Solution for injection/infusion |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

PRV-015 600 mg SC injection q2w for 24 weeks.

| Number of subjects in period 1^[1] | Placebo | PRV-015 100 mg | PRV-015 300 mg |
|---|---------|----------------|----------------|
| Started | 57 | 56 | 57 |
| Received treatment | 57 | 56 | 57 |
| Completed | 51 | 47 | 51 |
| Not completed | 6 | 9 | 6 |
| Consent withdrawn by subject | 3 | 5 | 5 |
| Unspecified | 1 | 3 | 1 |
| Lost to follow-up | 1 | 1 | - |
| Investigator or Sponsor judgement | 1 | - | - |

| Number of subjects in period 1^[1] | PRV-015 600 mg |
|---|----------------|
| Started | 56 |
| Received treatment | 54 |
| Completed | 49 |
| Not completed | 7 |
| Consent withdrawn by subject | 6 |
| Unspecified | - |
| Lost to follow-up | - |
| Investigator or Sponsor judgement | 1 |

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 388 participants entered the placebo run-in period. 1 participant never received treatment

and was not started after signing the ICF. 9 participants discontinued during run-in or were not dosed. 27 participants were run-in failures. 126 participants were randomization failures. A total of 226 participants were enrolled and randomized in the study.

Baseline characteristics

Reporting groups

| | |
|--|----------------|
| Reporting group title | Placebo |
| Reporting group description: Participants received placebo matching with PRV-015 subcutaneous (SC) injection every 2 weeks (q2w) in double-blind treatment period for 24 weeks. | |
| Reporting group title | PRV-015 100 mg |
| Reporting group description: Participants received PRV-015 100 milligram (mg) SC injection q2w in double-blind treatment period for 24 weeks. | |
| Reporting group title | PRV-015 300 mg |
| Reporting group description: Participants received PRV-015 300 mg SC injection q2w in double-blind treatment period for 24 weeks. | |
| Reporting group title | PRV-015 600 mg |
| Reporting group description: Participants received PRV-015 600 mg SC injection q2w in double-blind treatment period for 24 weeks. | |

| Reporting group values | Placebo | PRV-015 100 mg | PRV-015 300 mg |
|------------------------------------|---------|----------------|----------------|
| Number of subjects | 57 | 56 | 57 |
| Age Categorical Units: Subjects | | | |

| | | | |
|--|-----------------|-----------------|-----------------|
| Age Continuous Units: years arithmetic mean standard deviation | 41.0 ± 14.53 | 41.9 ± 14.82 | 39.0 ± 12.25 |
| Gender Categorical Units: Subjects | | | |
| Female | 53 | 38 | 50 |
| Male | 4 | 18 | 7 |
| Race Units: Subjects | | | |
| Black or African American | 0 | 1 | 0 |
| White | 57 | 55 | 56 |
| Not Reported | 0 | 0 | 0 |
| Unknown | 0 | 0 | 0 |
| Multiple | 0 | 0 | 1 |
| CeD PRO Abdominal Symptoms Domain Score | | | |
| The CeD PRO questionnaire was captured daily in the electronic (e)Diary. The questionnaire included 9 items: abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stool, nausea, headache and tiredness. Participants were asked to rate their symptom severity on an 11-point scale and scores range from 0 (not experiencing the symptom) to 10 (the worst possible symptom experience). Abdominal Symptoms domain included abdominal cramping, abdominal pain, bloating and gas. Total score for abdominal symptoms domain range from 0 to 40. Higher scores indicated worse outcome. | | | |
| Units: Subjects | | | |
| Score: <3 | 13 | 13 | 13 |
| Score: ≥3 | 44 | 43 | 44 |
| Stratification Factor Villous Height-to-Crypt Depth Ratio (VH:CD) | | | |

| | | | |
|---|----|----|----|
| The CeD PRO questionnaire was captured daily in the eDiary. The questionnaire included 9 items: abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stool, nausea, headache and tiredness. Participants were asked to rate their symptom severity on an 11-point scale and scores range from 0 (not experiencing the symptom) to 10 (the worst possible symptom experience). Abdominal Symptoms domain included abdominal cramping, abdominal pain, bloating and gas. Total score for abdominal symptoms domain range from 0 to 40. Higher scores indicated worse outcome. | | | |
| Units: Subjects | | | |
| Score: <2 | 37 | 37 | 37 |
| Score: >=2 | 20 | 19 | 20 |

| | | | |
|-------------------------------|----------------|-------|--|
| Reporting group values | PRV-015 600 mg | Total | |
| Number of subjects | 56 | 226 | |
| Age Categorical | | | |
| Units: Subjects | | | |

| | | | |
|---|---------|-----|--|
| Age Continuous | | | |
| Units: years | | | |
| arithmetic mean | 37.9 | | |
| standard deviation | ± 12.58 | - | |
| Gender Categorical | | | |
| Units: Subjects | | | |
| Female | 45 | 186 | |
| Male | 11 | 40 | |
| Race | | | |
| Units: Subjects | | | |
| Black or African American | 0 | 1 | |
| White | 53 | 221 | |
| Not Reported | 2 | 2 | |
| Unknown | 1 | 1 | |
| Multiple | 0 | 1 | |
| CeD PRO Abdominal Symptoms Domain Score | | | |

The CeD PRO questionnaire was captured daily in the electronic (e)Diary. The questionnaire included 9 items: abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stool, nausea, headache and tiredness. Participants were asked to rate their symptom severity on an 11-point scale and scores range from 0 (not experiencing the symptom) to 10 (the worst possible symptom experience). Abdominal Symptoms domain included abdominal cramping, abdominal pain, bloating and gas. Total score for abdominal symptoms domain range from 0 to 40. Higher scores indicated worse outcome.

| | | | |
|---|----|-----|--|
| Units: Subjects | | | |
| Score: <3 | 13 | 52 | |
| Score: >=3 | 43 | 174 | |
| Stratification Factor Villous Height-to-Crypt Depth Ratio (VH:CD) | | | |

The CeD PRO questionnaire was captured daily in the eDiary. The questionnaire included 9 items: abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stool, nausea, headache and tiredness. Participants were asked to rate their symptom severity on an 11-point scale and scores range from 0 (not experiencing the symptom) to 10 (the worst possible symptom experience). Abdominal Symptoms domain included abdominal cramping, abdominal pain, bloating and gas. Total score for abdominal symptoms domain range from 0 to 40. Higher scores indicated worse outcome.

| | | | |
|-----------------|----|-----|--|
| Units: Subjects | | | |
| Score: <2 | 36 | 147 | |
| Score: >=2 | 20 | 79 | |

End points

End points reporting groups

| | |
|--|----------------|
| Reporting group title | Placebo |
| Reporting group description: Participants received placebo matching with PRV-015 subcutaneous (SC) injection every 2 weeks (q2w) in double-blind treatment period for 24 weeks. | |
| Reporting group title | PRV-015 100 mg |
| Reporting group description: Participants received PRV-015 100 milligram (mg) SC injection q2w in double-blind treatment period for 24 weeks. | |
| Reporting group title | PRV-015 300 mg |
| Reporting group description: Participants received PRV-015 300 mg SC injection q2w in double-blind treatment period for 24 weeks. | |
| Reporting group title | PRV-015 600 mg |
| Reporting group description: Participants received PRV-015 600 mg SC injection q2w in double-blind treatment period for 24 weeks. | |

Primary: Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Abdominal Symptoms Domain Score Through Week 24

| | |
|---|--|
| End point title | Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Abdominal Symptoms Domain Score Through Week 24 |
| End point description: The CeD PRO questionnaire was captured daily in the eDiary. The questionnaire included 9 items: abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stool, nausea, headache and tiredness. Participants were asked to rate their symptom severity on an 11-point scale and scores range from 0 (not experiencing the symptom) to 10 (the worst possible symptom experience). Abdominal Symptoms domain included abdominal cramping, abdominal pain, bloating and gas. Total score for abdominal symptoms domain range from 0 to 40. Higher scores indicated worse outcome. Baseline abdominal symptoms domain score was defined as the average of the daily scores for the last week of the placebo run-in period. The modified intent-to-treat (mITT) analysis set included all randomized participants who received at least 1 dose of double-blind treatment. Only participants with data collected at baseline and up to Week 24 are reported. | |
| End point type | Primary |
| End point timeframe: Baseline (average of Day -7 to Day -1) up to Week 24 | |

| End point values | Placebo | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg |
|--|------------------------|------------------------|------------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 55 | 56 | 52 |
| Units: score on a scale | | | | |
| least squares mean (confidence interval 95%) | -1.32 (-1.66 to -0.98) | -1.28 (-1.62 to -0.94) | -1.21 (-1.55 to -0.88) | -1.28 (-1.63 to -0.93) |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Treatment difference in CeD PRO questionnaire 1 |
| Statistical analysis description: | |
| Estimates/p-value are from a mixed model for repeated measures (MMRM) with treatment, week, and treatment by week as fixed effects; continuous baseline CeD PRO Abdominal Symptoms domain score and baseline VH:CD ratio as covariates, and participant as a random effect. | |
| Comparison groups | Placebo v PRV-015 100 mg |
| Number of subjects included in analysis | 111 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.8543 |
| Method | MMRM |
| Parameter estimate | Least square (LS) mean difference |
| Point estimate | 0.04 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.43 |
| upper limit | 0.52 |

| | |
|---|---|
| Statistical analysis title | Treatment difference in CeD PRO questionnaire 3 |
| Statistical analysis description: | |
| Estimates/p-value are from a MMRM with treatment, week, and treatment by week as fixed effects; continuous baseline CeD PRO Abdominal Symptoms domain score and baseline VH:CD ratio as covariates, and participant as a random effect. | |
| Comparison groups | Placebo v PRV-015 600 mg |
| Number of subjects included in analysis | 108 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.8705 |
| Method | MMRM |
| Parameter estimate | LS mean difference |
| Point estimate | 0.04 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.45 |
| upper limit | 0.53 |

| | |
|---|---|
| Statistical analysis title | Treatment difference in CeD PRO questionnaire 2 |
| Statistical analysis description: | |
| Estimates/p-value are from a MMRM with treatment, week, and treatment by week as fixed effects; continuous baseline CeD PRO Abdominal Symptoms domain score and baseline VH:CD ratio as covariates, and participant as a random effect. | |
| Comparison groups | Placebo v PRV-015 300 mg |

| | |
|---|--------------------|
| Number of subjects included in analysis | 112 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.6552 |
| Method | MMRM |
| Parameter estimate | LS mean difference |
| Point estimate | 0.11 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.37 |
| upper limit | 0.59 |

Secondary: Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Diarrhea and Loose Stool Domain Score Through Week 24

| | |
|-----------------|--|
| End point title | Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Diarrhea and Loose Stool Domain Score Through Week 24 |
|-----------------|--|

End point description:

The CeD PRO questionnaire was captured daily in the eDiary. The questionnaire included 9 items: abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stool, nausea, headache and tiredness. Participants were asked to rate their symptom severity on an 11-point scale and scores range from 0 (not experiencing the symptom) to 10 (the worst possible symptom experience). Diarrhea and loose stool domain included diarrhea and loose stool. Total score for diarrhea and loose stool domain range from 0 to 20. Higher scores indicated worse outcome. Baseline diarrhea and loose stool domain score was defined as the average of the daily scores for the last week of the placebo run-in period. The mITT analysis set included all randomized participants who received at least 1 dose of double-blind treatment. Only participants with data collected at baseline and up to Week 24 are reported.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (average of Day -7 to Day -1) up to Week 24

| End point values | Placebo | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg |
|--|------------------------|------------------------|------------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 55 | 56 | 52 |
| Units: score on a scale | | | | |
| least squares mean (confidence interval 95%) | -0.77 (-1.15 to -0.40) | -0.66 (-1.04 to -0.28) | -1.02 (-1.39 to -0.64) | -1.07 (-1.46 to -0.68) |

Statistical analyses

| | |
|----------------------------|---|
| Statistical analysis title | Treatment difference in CeD PRO questionnaire 1 |
|----------------------------|---|

Statistical analysis description:

Estimates/p-value are from a MMRM with treatment, week, and treatment by week as fixed effects; continuous baseline CeD PRO Abdominal Symptoms domain score and baseline VH:CD ratio as covariates, and participant as a random effect.

| | |
|-------------------|--------------------------|
| Comparison groups | Placebo v PRV-015 100 mg |
|-------------------|--------------------------|

| | |
|---|--------------------|
| Number of subjects included in analysis | 111 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.6757 |
| Method | MMRM |
| Parameter estimate | LS mean difference |
| Point estimate | 0.11 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.42 |
| upper limit | 0.65 |

| | |
|-----------------------------------|---|
| Statistical analysis title | Treatment difference in CeD PRO questionnaire 3 |
|-----------------------------------|---|

Statistical analysis description:

Estimates/p-value are from a MMRM with treatment, week, and treatment by week as fixed effects; continuous baseline CeD PRO Abdominal Symptoms domain score and baseline VH:CD ratio as covariates, and participant as a random effect.

| | |
|---|--------------------------|
| Comparison groups | Placebo v PRV-015 600 mg |
| Number of subjects included in analysis | 108 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.2791 |
| Method | MMRM |
| Parameter estimate | LS mean difference |
| Point estimate | -0.3 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.84 |
| upper limit | 0.24 |

| | |
|-----------------------------------|---|
| Statistical analysis title | Treatment difference in CeD PRO questionnaire 2 |
|-----------------------------------|---|

Statistical analysis description:

Estimates/p-value are from a MMRM with treatment, week, and treatment by week as fixed effects; continuous baseline CeD PRO Abdominal Symptoms domain score and baseline VH:CD ratio as covariates, and participant as a random effect.

| | |
|---|--------------------------|
| Comparison groups | Placebo v PRV-015 300 mg |
| Number of subjects included in analysis | 112 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.3645 |
| Method | MMRM |
| Parameter estimate | LS mean difference |
| Point estimate | -0.25 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.78 |
| upper limit | 0.29 |

Secondary: Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Total Gastrointestinal (GI) Score Through Week 24

| | |
|-----------------|--|
| End point title | Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Total Gastrointestinal (GI) Score Through Week 24 |
|-----------------|--|

End point description:

The CeD PRO questionnaire was captured daily in the eDiary. The questionnaire included 9 items: abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stool, nausea, headache and tiredness. Participants were asked to rate their symptom severity on an 11-point scale and scores range from 0 (not experiencing the symptom) to 10 (the worst possible symptom experience). Total GI domain included abdominal symptoms domain, diarrhea, loose stool and nausea. Total GI score range from 0 to 70. Higher scores indicated worse outcome. Baseline GI score was defined as the average of the daily scores for the last week of the placebo run-in period. The mITT analysis set included all randomized participants who received at least 1 dose of double-blind treatment. Only participants with data collected at baseline and up to Week 24 are reported.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (average of Day -7 to Day -1) up to Week 24

| End point values | Placebo | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg |
|--|------------------------|------------------------|------------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 55 | 56 | 52 |
| Units: score on a scale | | | | |
| least squares mean (confidence interval 95%) | -0.89 (-1.15 to -0.63) | -0.84 (-1.10 to -0.57) | -0.88 (-1.14 to -0.62) | -1.05 (-1.32 to -0.78) |

Statistical analyses

| | |
|----------------------------|---|
| Statistical analysis title | Treatment difference in CeD PRO questionnaire 1 |
|----------------------------|---|

Statistical analysis description:

Estimates/p-value are from a MMRM with treatment, week, and treatment by week as fixed effects; continuous baseline CeD PRO Abdominal Symptoms domain score and baseline VH:CD ratio as covariates, and participant as a random effect.

| | |
|---|--------------------------|
| Comparison groups | Placebo v PRV-015 100 mg |
| Number of subjects included in analysis | 111 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.7829 |
| Method | MMRM |
| Parameter estimate | LS mean difference |
| Point estimate | 0.05 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.32 |
| upper limit | 0.42 |

| | |
|-----------------------------------|---|
| Statistical analysis title | Treatment difference in CeD PRO questionnaire 3 |
|-----------------------------------|---|

Statistical analysis description:

Estimates/p-value are from a MMRM with treatment, week, and treatment by week as fixed effects; continuous baseline CeD PRO Abdominal Symptoms domain score and baseline VH:CD ratio as covariates, and participant as a random effect.

| | |
|---|--------------------------|
| Comparison groups | Placebo v PRV-015 600 mg |
| Number of subjects included in analysis | 108 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.4107 |
| Method | MMRM |
| Parameter estimate | LS mean difference |
| Point estimate | -0.16 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.54 |
| upper limit | 0.22 |

| | |
|-----------------------------------|---|
| Statistical analysis title | Treatment difference in CeD PRO questionnaire 2 |
|-----------------------------------|---|

Statistical analysis description:

Estimates/p-value are from a MMRM with treatment, week, and treatment by week as fixed effects; continuous baseline CeD PRO Abdominal Symptoms domain score and baseline VH:CD ratio as covariates, and participant as a random effect.

| | |
|---|--------------------------|
| Comparison groups | Placebo v PRV-015 300 mg |
| Number of subjects included in analysis | 112 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.9503 |
| Method | MMRM |
| Parameter estimate | LS mean difference |
| Point estimate | 0.01 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.36 |
| upper limit | 0.38 |

Secondary: Absolute Change From Baseline in Intraepithelial Lymphocyte (IEL)

Density at Week 24

| | |
|-----------------|--|
| End point title | Absolute Change From Baseline in Intraepithelial Lymphocyte (IEL) Density at Week 24 |
|-----------------|--|

End point description:

The small intestinal mucosal inflammation was measured by IEL density using immunohistochemistry. Baseline was defined as IEL density from the esophagogastroduodenoscopy biopsy conducted during the run-in period. The mITT analysis set included all randomized participants who received at least 1 dose of double-blind treatment. Only participants with data collected at baseline and Week 24 are reported.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline to Week 24

| End point values | Placebo | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg |
|--|-----------------------|----------------------|------------------------|------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 51 | 49 | 51 | 48 |
| Units: cells/100 epithelial cells | | | | |
| least squares mean (confidence interval 95%) | -0.39 (-3.82 to 3.03) | 1.54 (-1.99 to 5.07) | -4.11 (-7.56 to -0.66) | -4.53 (-8.13 to -0.93) |

Statistical analyses

| | |
|----------------------------|---------------------------------------|
| Statistical analysis title | Treatment difference in IEL density 1 |
|----------------------------|---------------------------------------|

Statistical analysis description:

Estimates/p-value are from an analysis of covariance (ANCOVA) model with treatment as a fixed effect. Continuous baseline CeD PRO Abdominal Symptoms domain score and baseline VH:CD ratio are included as covariates.

| | |
|---|--------------------------|
| Comparison groups | Placebo v PRV-015 100 mg |
| Number of subjects included in analysis | 100 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.4397 |
| Method | ANCOVA |
| Parameter estimate | LS mean difference |
| Point estimate | 1.94 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3 |
| upper limit | 6.87 |

| | |
|----------------------------|---------------------------------------|
| Statistical analysis title | Treatment difference in IEL density 3 |
|----------------------------|---------------------------------------|

Statistical analysis description:

Estimates/p-value are from an ANCOVA model with treatment as a fixed effect. Continuous baseline CeD PRO Abdominal Symptoms domain score and baseline VH:CD ratio are included as covariates.

| | |
|-------------------|--------------------------|
| Comparison groups | Placebo v PRV-015 600 mg |
|-------------------|--------------------------|

| | |
|---|--------------------|
| Number of subjects included in analysis | 99 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.1021 |
| Method | ANCOVA |
| Parameter estimate | LS mean difference |
| Point estimate | -4.14 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -9.11 |
| upper limit | 0.83 |

| | |
|-----------------------------------|---------------------------------------|
| Statistical analysis title | Treatment difference in IEL density 2 |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Estimates/p-value are from an ANCOVA model with treatment as a fixed effect. Continuous baseline CeD PRO Abdominal Symptoms domain score and baseline VH:CD ratio are included as covariates.

| | |
|---|--------------------------|
| Comparison groups | Placebo v PRV-015 300 mg |
| Number of subjects included in analysis | 102 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.1337 |
| Method | ANCOVA |
| Parameter estimate | LS mean difference |
| Point estimate | -3.72 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -8.58 |
| upper limit | 1.15 |

Secondary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events of Special Interest (AESIs)

| | |
|-----------------|---|
| End point title | Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events of Special Interest (AESIs) |
|-----------------|---|

End point description:

An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE was defined as any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. AESIs included severe opportunistic infections and hypersensitivity reactions of at least moderate severity. A TEAE was defined as an AE that occurred from the first dose of post-randomization study drug administration through the end of the study. The Safety analysis set included all participants who received at least 1 dose of the study drug post-randomization.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days

| End point values | Placebo | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg |
|---|-----------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 57 | 56 | 57 | 54 |
| Units: participants | | | | |
| Any TEAE | 34 | 34 | 36 | 29 |
| TEAE leading to study treatment discontinuation | 1 | 1 | 2 | 0 |
| Treatment-emergent SAE | 1 | 0 | 0 | 1 |
| Treatment-emergent AESI | 2 | 1 | 1 | 1 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Potentially Clinically Important Changes in Hematology

| | |
|-----------------|--|
| End point title | Number of Participants With Potentially Clinically Important Changes in Hematology |
|-----------------|--|

End point description:

Blood samples were collected to determine the hematology laboratory important changes. The Safety analysis set included all participants who received at least 1 dose of the study drug post-randomization. Only participants with data collected are reported. CHG= Change from baseline hemoglobin.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days

| End point values | Placebo | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg |
|-----------------------------|-----------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 57 | 56 | 57 | 53 |
| Units: participants | | | | |
| Hemoglobin: CHG <=-20 | 0 | 0 | 1 | 2 |
| Neutrophils: <1 | 2 | 1 | 4 | 2 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Potentially Clinically Important Changes in Clinical Chemistry

| | |
|-----------------|--|
| End point title | Number of Participants With Potentially Clinically Important Changes in Clinical Chemistry |
|-----------------|--|

End point description:

Blood samples were collected to determine the clinical chemistry laboratory important changes. The Safety analysis set included all participants who received at least 1 dose of the study drug post-randomization. Only participants with data collected are reported. Here, ULN= Upper limit of normal, mmol/L= millimoles per liter and mcmol/L= micromoles per liter.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days

| End point values | Placebo | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg |
|---|-----------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 57 | 56 | 57 | 53 |
| Units: participants | | | | |
| Alanine Aminotransferase: $\geq 3 \times$ ULN | 1 | 4 | 1 | 2 |
| Aspartate Aminotransferase: $\geq 3 \times$ ULN | 1 | 2 | 0 | 0 |
| Chloride: > 125 mmol/L | 1 | 0 | 1 | 0 |
| Creatinine: ≥ 132 mcmol/L | 1 | 1 | 0 | 0 |
| Potassium: > 6 mmol/L | 0 | 0 | 2 | 1 |
| Sodium: < 125 mmol/L | 0 | 0 | 1 | 0 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Potentially Clinically Important Changes in Urinalysis

| | |
|-----------------|--|
| End point title | Number of Participants With Potentially Clinically Important Changes in Urinalysis |
|-----------------|--|

End point description:

Urine samples were collected to determine the important changes in urine. The Safety analysis set included all participants who received at least 1 dose of the study drug post-randomization. Here, n= number of participants with data collected for each specific parameter and 99999= no participant was analyzed. Squamous Epithelial Cells= SEC, TNTC= Too numerous to count, LPF= Low power field and HPF= High power field.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days

| End point values | Placebo | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg |
|--|-----------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 57 | 56 | 57 | 53 |
| Units: participants | | | | |
| Bacteria: Present (n=54,51,55,47) | 54 | 51 | 55 | 47 |
| Crystals: Present (n=3,4,2,5) | 3 | 4 | 2 | 5 |
| Erythrocytes (/HPF): Many/TNTC (n=55,56,56,53) | 1 | 0 | 4 | 3 |
| Glucose: 3+/4+ (n=57,56,57,53) | 1 | 2 | 1 | 0 |
| Hyaline Casts (/HPF): Few/Moderate/Many(n=8,7,9,7) | 3 | 2 | 3 | 0 |
| Hyaline Casts (/LPF): Few/Moderate/Many(n=0,2,1,0) | 99999 | 1 | 1 | 99999 |
| Ketones: 3+ (n=57,56,57,53) | 1 | 2 | 3 | 1 |
| Leukocyte Esterase: 3+/4+ (n=57,56,57,53) | 19 | 12 | 16 | 15 |
| Leukocytes (/HPF): Many/TNTC (n=56,56,57,53) | 11 | 3 | 9 | 7 |
| Nitrite: Positive (n=57,56,57,53) | 2 | 1 | 2 | 1 |
| SEC (/HPF): Many/TNTC(n=54,54,54,49) | 6 | 0 | 6 | 8 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Potentially Clinically Important Changes in Vital Signs and Body Weight

| | |
|-----------------|---|
| End point title | Number of Participants With Potentially Clinically Important Changes in Vital Signs and Body Weight |
|-----------------|---|

End point description:

Participant's vital signs and body weight were examined to determine the important changes. Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate. The Safety analysis set included all participants who received at least 1 dose of the study drug post-randomization. Here, mmHg= millimeters of mercury, DFB= Decrease from baseline and IFB= Increase from baseline.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days

| End point values | Placebo | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg |
|-----------------------------------|-----------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 57 | 56 | 57 | 54 |
| Units: participants | | | | |
| SBP: <=95 mmHg and DFB >=20 mmHg | 5 | 2 | 6 | 1 |
| SBP: >=160 mmHg and IFB >=20 mmHg | 2 | 1 | 0 | 1 |
| DBP: >=110 mmHg and IFB >=10 mmHg | 0 | 0 | 0 | 1 |

| | | | | |
|--|---|----|----|---|
| Heart Rate: <=50 bpm and DFB >=20 bpm | 1 | 1 | 1 | 0 |
| Heart Rate: >=120 bpm and IFB >=20 bpm | 0 | 0 | 0 | 1 |
| Body weight: >=5% DFB | 8 | 11 | 9 | 7 |
| Body weight: >=5% IFB | 9 | 8 | 13 | 5 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Anti-PRV-015 Antibodies

| | |
|-----------------|--|
| End point title | Number of Participants With Anti-PRV-015 Antibodies ^[1] |
|-----------------|--|

End point description:

Blood samples were collected to determine the presence of anti-drug antibodies by immunoassay. The Immunogenicity analysis set included participants who were randomized, dosed, and had at least 1 evaluable immunogenicity assessment. Here, n= number of participants with data collected at specific time point.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1) and Weeks 2, 4, 12, 22, 24 and 28

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only participants treated with the study drug are analyzed for this endpoint.

| End point values | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg | |
|-----------------------------|-----------------|-----------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 53 | 56 | 53 | |
| Units: participants | | | | |
| Baseline (n=52,52,50) | 3 | 8 | 7 | |
| Week 2 (n=53,56,51) | 8 | 9 | 9 | |
| Week 4 (n=52,51,48) | 5 | 6 | 5 | |
| Week 12 (n=51,51,53) | 4 | 5 | 4 | |
| Week 22 (n=49,49,48) | 4 | 4 | 2 | |
| Week 24 (n=49,51,49) | 4 | 3 | 2 | |
| Week 28 (n=50,52,48) | 4 | 3 | 2 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Minimum Serum Concentrations (Cmin) of PRV-015

| | |
|-----------------|---|
| End point title | Minimum Serum Concentrations (Cmin) of PRV-015 ^[2] |
|-----------------|---|

End point description:

Blood samples were collected at specified timepoints to determine the Cmin. The Pharmacokinetic (PK) analysis set included participants who were randomized, dosed, and had at least 1 post-dose evaluable PK assessment. Here, n= number of participants with data collected at specific time point. Only participants with data collected at specific time point are reported. Participants were not analyzed at

pre-dose on Day 1 as the study drug was not administered. Hence, no data collected.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Pre-dose on Day 1 and Weeks 2, 4, 8, 12, 16, 20, 22, 24 and 28

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only participants treated with the study drug are analyzed for this endpoint.

| End point values | PRV-015 100 mg | PRV-015 300 mg | PRV-015 600 mg | |
|---|-----------------|-----------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 52 | 53 | 48 | |
| Units: nanogram per milliliter | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Pre-dose on Day 1 (n=52,51,48) | 99999 (± 99999) | 99999 (± 99999) | 99999 (± 99999) | |
| Week 2 (n=46,53,46) | 8778 (± 74.1) | 27820 (± 39.8) | 66400 (± 46.1) | |
| Week 4 (n=36,43,39) | 15140 (± 42.8) | 51190 (± 42.1) | 98420 (± 49.4) | |
| Week 8 (n=31,40,33) | 21790 (± 46.4) | 61990 (± 66.5) | 142600 (± 43.7) | |
| Week 12 (n=28,33,32) | 23630 (± 46.8) | 73150 (± 56.5) | 168300 (± 37.9) | |
| Week 16 (n=25,27,26) | 22960 (± 46.7) | 75830 (± 65.1) | 166700 (± 44.9) | |
| Week 20 (n=20,25,21) | 27000 (± 42.5) | 74110 (± 67.8) | 186400 (± 51.2) | |
| Week 22 (n=20,22,21) | 25410 (± 36.2) | 73120 (± 64.2) | 181000 (± 55.6) | |
| Week 24 (n=18,18,18) | 26680 (± 40.3) | 72400 (± 49.6) | 160500 (± 47.5) | |
| Week 28 (n=26,25,27) | 10210 (± 58.0) | 32810 (± 80.0) | 69370 (± 78.3) | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days

Adverse event reporting additional description:

The Safety analysis set included all participants who received at least 1 dose of the study drug post-randomization.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 27.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|----------------|
| Reporting group title | Placebo Run-In |
|-----------------------|----------------|

| | |
|--------------------------------|--|
| Reporting group description: - | |
|--------------------------------|--|

| | |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

| | |
|--------------------------------|--|
| Reporting group description: - | |
|--------------------------------|--|

| | |
|-----------------------|---------------|
| Reporting group title | PRV-015 100mg |
|-----------------------|---------------|

| | |
|--------------------------------|--|
| Reporting group description: - | |
|--------------------------------|--|

| | |
|-----------------------|---------------|
| Reporting group title | PRV-015 300mg |
|-----------------------|---------------|

| | |
|--------------------------------|--|
| Reporting group description: - | |
|--------------------------------|--|

| | |
|-----------------------|---------------|
| Reporting group title | PRV-015 600mg |
|-----------------------|---------------|

| | |
|--------------------------------|--|
| Reporting group description: - | |
|--------------------------------|--|

| Serious adverse events | Placebo Run-In | Placebo | PRV-015 100mg |
|---|-----------------|----------------|----------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 2 / 387 (0.52%) | 1 / 57 (1.75%) | 0 / 56 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Injury, poisoning and procedural complications | | | |
| Pelvic Fracture | | | |
| subjects affected / exposed | 0 / 387 (0.00%) | 1 / 57 (1.75%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Presyncope | | | |
| subjects affected / exposed | 0 / 387 (0.00%) | 0 / 57 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |

| | | | |
|---|-----------------|----------------|----------------|
| Intussusception | | | |
| subjects affected / exposed | 1 / 387 (0.26%) | 0 / 57 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Gluten Sensitivity | | | |
| subjects affected / exposed | 1 / 387 (0.26%) | 0 / 57 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|----------------|--|
| Serious adverse events | PRV-015 300mg | PRV-015 600mg | |
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 57 (0.00%) | 1 / 54 (1.85%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | | | |
| Injury, poisoning and procedural complications | | | |
| Pelvic Fracture | | | |
| subjects affected / exposed | 0 / 57 (0.00%) | 0 / 54 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| Presyncope | | | |
| subjects affected / exposed | 0 / 57 (0.00%) | 1 / 54 (1.85%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Intussusception | | | |
| subjects affected / exposed | 0 / 57 (0.00%) | 0 / 54 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| Gluten Sensitivity | | | |
| subjects affected / exposed | 0 / 57 (0.00%) | 0 / 54 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Placebo Run-In | Placebo | PRV-015 100mg |
|---|-----------------|------------------|------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 0 / 387 (0.00%) | 22 / 57 (38.60%) | 18 / 56 (32.14%) |
| Nervous system disorders | | | |
| Migraine | | | |
| subjects affected / exposed | 0 / 387 (0.00%) | 4 / 57 (7.02%) | 2 / 56 (3.57%) |
| occurrences (all) | 0 | 4 | 2 |
| Headache | | | |
| subjects affected / exposed | 0 / 387 (0.00%) | 1 / 57 (1.75%) | 4 / 56 (7.14%) |
| occurrences (all) | 0 | 2 | 4 |
| General disorders and administration site conditions | | | |
| Injection Site Bruising | | | |
| subjects affected / exposed | 0 / 387 (0.00%) | 0 / 57 (0.00%) | 0 / 56 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injection Site Erythema | | | |
| subjects affected / exposed | 0 / 387 (0.00%) | 2 / 57 (3.51%) | 3 / 56 (5.36%) |
| occurrences (all) | 0 | 2 | 8 |
| Injection Site Reaction | | | |
| subjects affected / exposed | 0 / 387 (0.00%) | 1 / 57 (1.75%) | 3 / 56 (5.36%) |
| occurrences (all) | 0 | 2 | 4 |
| Gastrointestinal disorders | | | |
| Abdominal Distension | | | |
| subjects affected / exposed | 0 / 387 (0.00%) | 1 / 57 (1.75%) | 3 / 56 (5.36%) |
| occurrences (all) | 0 | 1 | 4 |
| Abdominal Pain | | | |
| subjects affected / exposed | 0 / 387 (0.00%) | 3 / 57 (5.26%) | 3 / 56 (5.36%) |
| occurrences (all) | 0 | 3 | 3 |
| Nausea | | | |
| subjects affected / exposed | 0 / 387 (0.00%) | 1 / 57 (1.75%) | 2 / 56 (3.57%) |
| occurrences (all) | 0 | 1 | 2 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 387 (0.00%) | 6 / 57 (10.53%) | 1 / 56 (1.79%) |
| occurrences (all) | 0 | 7 | 1 |
| Skin and subcutaneous tissue disorders | | | |

| | | | |
|---|-----------------|----------------|----------------|
| Rash | | | |
| subjects affected / exposed | 0 / 387 (0.00%) | 4 / 57 (7.02%) | 0 / 56 (0.00%) |
| occurrences (all) | 0 | 4 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 387 (0.00%) | 2 / 57 (3.51%) | 3 / 56 (5.36%) |
| occurrences (all) | 0 | 2 | 3 |
| Infections and infestations | | | |
| Covid-19 | | | |
| subjects affected / exposed | 0 / 387 (0.00%) | 3 / 57 (5.26%) | 5 / 56 (8.93%) |
| occurrences (all) | 0 | 3 | 5 |
| Upper Respiratory Tract Infection | | | |
| subjects affected / exposed | 0 / 387 (0.00%) | 5 / 57 (8.77%) | 3 / 56 (5.36%) |
| occurrences (all) | 0 | 6 | 5 |

| | | | |
|---|------------------|------------------|--|
| Non-serious adverse events | PRV-015 300mg | PRV-015 600mg | |
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 22 / 57 (38.60%) | 19 / 54 (35.19%) | |
| Nervous system disorders | | | |
| Migraine | | | |
| subjects affected / exposed | 1 / 57 (1.75%) | 1 / 54 (1.85%) | |
| occurrences (all) | 1 | 1 | |
| Headache | | | |
| subjects affected / exposed | 5 / 57 (8.77%) | 2 / 54 (3.70%) | |
| occurrences (all) | 5 | 2 | |
| General disorders and administration site conditions | | | |
| Injection Site Bruising | | | |
| subjects affected / exposed | 2 / 57 (3.51%) | 3 / 54 (5.56%) | |
| occurrences (all) | 2 | 3 | |
| Injection Site Erythema | | | |
| subjects affected / exposed | 3 / 57 (5.26%) | 2 / 54 (3.70%) | |
| occurrences (all) | 6 | 7 | |
| Injection Site Reaction | | | |
| subjects affected / exposed | 3 / 57 (5.26%) | 3 / 54 (5.56%) | |
| occurrences (all) | 6 | 9 | |
| Gastrointestinal disorders | | | |

| | | | |
|---|----------------------|---------------------|--|
| Abdominal Distension subjects affected / exposed occurrences (all) | 0 / 57 (0.00%) 0 | 2 / 54 (3.70%) 2 | |
| Abdominal Pain subjects affected / exposed occurrences (all) | 0 / 57 (0.00%) 0 | 4 / 54 (7.41%) 4 | |
| Nausea subjects affected / exposed occurrences (all) | 5 / 57 (8.77%) 5 | 3 / 54 (5.56%) 3 | |
| Diarrhoea subjects affected / exposed occurrences (all) | 4 / 57 (7.02%) 6 | 4 / 54 (7.41%) 4 | |
| Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all) | 3 / 57 (5.26%) 3 | 1 / 54 (1.85%) 2 | |
| Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all) | 0 / 57 (0.00%) 0 | 2 / 54 (3.70%) 2 | |
| Infections and infestations Covid-19 subjects affected / exposed occurrences (all) | 8 / 57 (14.04%) 8 | 5 / 54 (9.26%) 5 | |
| Upper Respiratory Tract Infection subjects affected / exposed occurrences (all) | 4 / 57 (7.02%) 4 | 4 / 54 (7.41%) 4 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---------------|--|
| 01 March 2021 | The antibody tests on the Day -14 visit (Visit -2) were removed to avoid any delay for the Day 0 visit and the start of study treatment. All urine samples were collected at each visit. The maximum levels of tissue transglutaminase and deamidated gluten peptide antibodies for inclusion was revised from 1.5 to 2.0 times the cutoff value for positivity. The Data Monitoring Committee member composition was updated. The window for the baseline endoscopy was increased to 12 days prior to Visit 2 to improve scheduling feasibility. Updated to allow the inclusion of participants with less common human leukocyte antigen types associated with celiac disease. Clarified the consenting procedures for participants undergoing rescreening. Corrected to include hemoglobin A1C at visits designated in the Schedule of Activities. Clarified the procedures for SAE reporting. |
| 24 March 2022 | The level of tissue transglutaminase and deamidated gluten peptide antibodies for study inclusion was revised from <2.0 to <3.0 times the cutoff value for positivity. Updated inclusion and exclusion criteria. The planned method for the analysis of delayed TEAEs in participants who discontinued study treatment was removed and deferred to the Statistical Analysis Plan. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported